Skip to content
Finance Investment, General News

Bonds are back in favour after years of neglect: new report

Stockspot 2 mins read

Once shunned by investors, bond ETFs are now back in favour with the market, with a record $18.2 billion tracking bond ETFs in Australia. New research from Stockspot also found that while growing at a rate of 42% per year over the last five years, bond ETFs now make up 12% of the $150 billion Australian ETF market.

These findings, released today in the latest 2023 Stockspot ETF Report also show that technology-driven ETFs, which hold exposure to big names like Amazon and Microsoft, and cryptocurrency ETFs were the best-performers over the last 12 months to 30 June 2023.

We’ve found that while bonds and the broader fixed-income asset class had experienced some of their worst performance in decades during 2022, bonds are attracting significant inflows in 2023,” Stockspot founder and CEO, Chris Brycki said.

“We’ve been researching the more than 250 ETFs on the ASX and Cboe Australia for 10 years now and this is the first time we’ve seen bond ETFs getting so much interest.”

Stockspot found that some commodity-linked ETFs had the biggest falls over the past year.

“The palladium-linked ETF (ETPMPD) and the oil-linked ETF (OOO) took falls of -33.5% and -32.5% respectively. Interestingly, OOO was the best-performing ETF in our 2022 Stockspot ETF Report, up 80% at the time,” Mr Brycki said.

“From gaining 80% in one year to losing 32% the following year serves as a very important reminder of the difficulty in trying to pick the winners and timing the market. Last year’s winner can easily be this year’s loser.”

Mr Brycki said investors should instead just focus on owning the whole market through simple, vanilla ETFs. “Our research has found that investing in a simple vanilla ETF is the safest way investors can gain exposure to the broader market without having to guess what will do well.” 

Active fund managers again found themselves in a fierce battle to retain their assets as the industry witnessed a tidal wave of outflows from active ETFs. Magellan's flagship ETF, MGOC, suffered heavy outflows, losing $2.4 billion - nearly a quarter of its total asset value. Magellan dominated the ranks, with three out of the five ETFs experiencing the most significant assets under management declines.

Download the 2023 Stockspot ETF report

 

 

 


Key Facts:

- A record $18.2 billion is now tracking bond ETFs in Australia.

- Bond ETFs now make up 12% of the $150 billion Australian ETF market.

- Some commodity-linked ETFs had the biggest falls over the past year.

 


About us:

About Stockspot

Stockspot is Australia’s leading online investment adviser and fund manager. Since 2013, we have helped thousands of Australians create financial freedom. We are an independent thought leader on wealth creation, guiding our clients on a better way to invest for the long-term. Our philosophy is built on the values of simplicity, consistency and discipline.

Clients can start with as little as $2,000 and the service is free for investments under $10,000 for the first six months. We make investing easy and affordable. Our investment strategies have achieved a eight-year track record of consistent positive returns.


Contact details:

Joseph Younes

0416 619 500

[email protected]

[email protected]

 

Media

More from this category

  • General News, Sport Recreation
  • 17/03/2026
  • 16:39
Allianz Australia

Allianz reveals under-pressure Australians are looking to football heroes for inspiration

Allianz Australia has today released new research, which shows that 68 per cent of surveyed Australians have faced adversity over the past twelve months,…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/03/2026
  • 10:25
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Advances StemSmart(TM) Manufacturing Scale-Up as Phase 2 Crohn’s Disease Trial Preparations Progress

Perth, Australia – 17 March 2026 | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has reached an important development milestone with the commencement of the first technology transfer manufacturing run of its patented StemSmart™ mesenchymal stem cell (MSC) process at leading Australian cell therapy manufacturer Q-Gen Cell Therapeutics. The initiation of the manufacturing run represents a key step in the transfer of the StemSmart™ manufacturing process to a large-scale clinical contract manufacturer that is then capable of providing adequate supply for Phase 2 clinical trials and future commercialisation. Q-Gen Cell Therapeutics, located within the QIMR Berghofer Medical Research Institute in Brisbane, is one…

  • Contains:
  • Environment, Finance Investment
  • 17/03/2026
  • 10:21
HESTA

HESTA launches search for Australia’s early childhood education champions

17 March 2026 The search for Australia’s most outstanding early childhood educators is underway with nominations opening today for the 2026 HESTA Early Childhood…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.